Menu

CME Corner

This activity has expired. CME/CE credit is no longer available and the following content may not be available or may not be up-to-date. For a list of current activities that offer CME/CE credit, click here.

Program Detail

Release Date: April-15-15
Credit Expiration Date: April-15-16

Faculty

Alpesh N. Amin, MD, MBA
Professor of Medicine
Chair, Department of Medicine
Executive Director, Hospitalist Program
University of California, Irvine
Irvine, CA

Credit Hours

0.75 AMA PRA Category 1 Credit

Medium

Mobile + Online on QuantiaMD

Program Description

Nonvalvular atrial fibrillation (AF) is the most common sustained cardiac arrhythmia encountered in clinical practice and afflicts more than 3 million people in the United States. Individuals with AF have 4 to 5 times greater risk for ischemic stroke and tend to experience more serious strokes than those without AF. Although most AF-related strokes could be prevented with anticoagulation therapy, many patients with AF are not receiving appropriate evidence-based therapy for stroke prevention. This activity will identify opportunities for cardiologists, primary care physicians, physician assistants, and nurse practitioners to overcome persistent barriers to the use of appropriate anticoagulation therapy for the prevention of stroke in patients with AF.

Program Developer/Facilitator


.

Target Audience

Primary care physicians, nurse practitioners, physician assistants, and other healthcare professionals interested in the prevention of stroke in atrial fibrillation.

Learning Objectives

Upon completion of this educational activity, the participant should be able to:

  1. Explain the appropriate use of tools to calculate stroke and bleeding risk in patients with AF.
  2. Describe recent changes to clinical practice guidelines and current evidence for best practices in the use of anticoagulation therapy for patients with AF.
  3. Describe the mechanisms of action of investigational drugs in late stages of development for stroke prevention in patients with AF.
  4. Select anticoagulation therapy for patients with AF based on the results of risk scoring assessments.

Disclosures

Alpesh N. Amin, MD, MBA, discloses the following relationships with commercial interests:
Consultant: Daiichi Sankyo, Inc.
Speakers bureau: Bristol-Myers Squibb and Pfizer Inc.

Rick Ricer, MD, Physician Reviewer, University of Cincinnati, has no conflicts of interest to disclose.
Susan P. Tyler, MEd, CMP, CHCP, FACEHP, University of Cincinnati, has no conflicts of interest to disclose.
Kathleen Hines, MCM Education editorial director, has no conflicts of interest to disclose.

The University of Cincinnati requires all faculty to disclose any planned discussion of an investigational and/or off-label use of a pharmaceutical product or device within their presentation. Participants should note that the use of products outside FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for approved indications.

In this educational activity, the faculty reports his presentation will not contain reference to investigational and/or off-label uses.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.  

Credit Statements

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati and MCM Education. The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.

The University of Cincinnati designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Release date: April 15, 2015
Last review date: April 15, 2015
Expiration date: April 15, 2016

Commercial Support Statements

Supported by independent educational grants from Daiichi Sankyo, Inc. and Boehringer Ingelheim.

Instructions

Completion Instructions

  1. Accessing Activity:
    * Link to and Log into program on QuantiaMD.com
    * Take the pre-test
    * Review the activity
    * Take the post-test and score 75%
    * You are allowed a total of 3 attempts
    * Complete the evaluation
    * View, print, or save a CME certificate verifying your
    credit/participation in this activity
  2. Computer Requirements: Minimum System Requirements: • Pentium III, 600 MHz or Equivalent Processor • 512 MB of RAM • Windows XP, Vista, or 7 • Mac OS X • 800x600 Monitor Resolution • 16-bit Color • 16 bit Sound Card with Speakers

Certificate Fee

$0.00

There is no charge for CME credit.

Disclaimer

© 2015 MCM Education. All rights reserved. None of the contents may be reproduced in any form without prior written permission from the publisher. The opinions expressed in this educational activity are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, the University of Cincinnati, Daiichi Sankyo, Inc. or Boehringer Ingelheim. Any medications, diagnostic procedures, or treatments discussed by the faculty should not be used by clinicians or other health care professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.

By clicking START PROGRAM I acknowledge that I have read the CME/CE information above.

Main Menu
EDITOR'S PICKS